US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 0.7918
- -0.0348-4.21%
Close Jul 19 16:00 ET
- 0.7999
- +0.0081+1.02%
Pre 08:05 ET
143.06MMarket Cap-3442P/E (TTM)
0.8400High0.7702Low1.73MVolume0.8400Open0.8266Pre Close1.37MTurnover1.03%Turnover RatioLossP/E (Static)180.67MShares1.070052wk High1.80P/B133.31MFloat Cap0.480052wk Low--Dividend TTM168.37MShs Float30.0000Historical High--Div YieldTTM8.44%Amplitude0.4000Historical Low0.7930Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Citius Pharmaceuticals Stock Forum
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunother...
Bloodstream Infections - From Threats to Solutions
Investorideas.com published the second part of a series on blood infections treatment, featuring Citius Pharmaceuticals (NASDAQ: CTXR). Citius has made significant advances in its late-stage product candidates, particularly Mino-Lok® for catheter-related bloodstream infections (CRBSIs). The Phase 3 trial of Mino-Lok® showed positive topline results, meeting primary and secondary endpoints with statistical si...
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Benzinga· May 31 13:061min
Citius Pharmaceuticals (CTXR.US)
0.746
+10.29%
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.
Disclaimer: This content is for inform
good morning everyone pay attention CTXR next month 4$
• Considered a new biologic by the FDA, LYMPHIR would potentially be eligible f...
No comment yet